A PILOT FEASIBILITY STUDY OF INTRACEREBRAL MICRODIALYSIS TO DETERMINE THE NEURO

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 该方案的总体目标是开发一种系统，通过直接确定这些药物是否可以穿过脑肿瘤患者的BBB，有效筛选可能用于I期和II期脑肿瘤临床试验的新药。该计划是在脑瘤患者接受活检或开颅手术时，将微透析导管置入肿瘤或邻近的大脑皮层。一旦患者从麻醉中恢复并在术后稳定，将给予她/他一定剂量的全身化疗药物（在本可行性研究中，将使用已知可穿过BBB的药物替莫唑胺），并进行脑内微透析以确定是否在透析液中回收任何药物，反映药物能够穿透BBB的程度。将脑肿瘤组织中的药物水平与血浆中的水平进行比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a system for efficiently screening new agents for potential use in Phase I and II brain tumor clinical trials by directly determining if these drugs can cross the BBB in patients with brain tumors. The plan is to place a microdialysis catheter into either the tumor or adjacent cerebral cortex when a brain tumor patient undergoes a biopsy or debulking craniotomy. Once the patient has recovered from the anesthesia and is stable post-operatively, s/he will be given a dose of a systemic chemotherapy agent (in this feasibility study temozolomide, a drug already known to cross the BBB, will be used), and intracerebral microdialysis will be performed to determine if any of the drug is recovered in the dialysate, reflecting the degree to which the drug is able to penetrate the BBB. Drug levels in the brain tumor interstitium will be compared to levels in the plasma.